Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En forskningsstudie som jämför hur väl olika doser av medicinen NN0519-0130 sänker blodsockret hos personer med typ 2-diabetes

18 september 2026 uppdaterad av: Novo Nordisk A/S

Undersökning av säkerheten och effekten av NNC0519-0130 en gång i veckan hos deltagare med typ 2-diabetes - en dosstudie

This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The study will test up to 7 different doses of NNC0519-0130. Which treatment participant will get is decided by chance. Participants will take 1-3 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 40 weeks.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Faktisk)

299

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • New South Wales
      • Campbelltown, New South Wales, Australien, 2560
        • Campbelltown Hospital
      • Macquarie Park, New South Wales, Australien, 2109
        • Macquarie University - Clinical Trials Unit
      • St Leonards, New South Wales, Australien, 2065
        • Royal North Shore Hospital
      • Sydney, New South Wales, Australien, 2148
        • Western Endocrine Blacktown
      • Sydney, New South Wales, Australien, 2148
        • Roger Chih Yu Chen
      • Wollongong, New South Wales, Australien, 2500
        • Illawarra Diabetes Service Clinical Trials & Research Unit
    • Queensland
      • Birtinya, Queensland, Australien, 4575
        • University of Sunshine Coast - Vitality Village
      • Meadowbrook, Queensland, Australien, 4131
        • Logan Hospital
    • South Australia
      • Oaklands Park, South Australia, Australien, 5046
        • Southern Adelaide Diabetes & Endocrine Services
    • Victoria
      • Box Hill, Victoria, Australien, 3128
        • Eastern Clinical Research Unit Box Hill
      • Camberwell, Victoria, Australien, 3124
        • Emeritus Research Melbourne
      • Heidelberg Heights, Victoria, Australien, 3081
        • Austin Health, Metabolic Disorders Centre
      • Parkville, Victoria, Australien, 3050
        • The Royal Melbourne Hospital
      • Parkville, Victoria, Australien, 3050
        • The Royal Melbourne Hospital - Diabetes & Endocrinology Department
    • Western Australia
      • Fremantle, Western Australia, Australien, 6160
        • Fremantle Hospital
    • California
      • Chula Vista, California, Förenta staterna, 91911
        • Velocity Clin Res-Chula Vista
      • Fresno, California, Förenta staterna, 93720
        • Valley Research
      • Inglewood, California, Förenta staterna, 90301
        • 310 Clinical Research
      • La Mesa, California, Förenta staterna, 91942
        • Velocity Clin Res San Diego
      • Lancaster, California, Förenta staterna, 93534
        • First Valley Med Grp Lancaster
      • Lomita, California, Förenta staterna, 90717
        • Torrance Clin Res Inst, Inc.
      • Los Alamitos, California, Förenta staterna, 90720
        • Pacific Clinical Studies
      • Los Angeles, California, Förenta staterna, 90057
        • Velocity Clinical Research Westlake
      • Montclair, California, Förenta staterna, 91763
        • Catalina Research Institute, LLC
      • San Diego, California, Förenta staterna, 92123
        • Artemis Insitute for Clin Res
      • Toluca Lake, California, Förenta staterna, 91602
        • Med Partners, Inc.
      • Torrance, California, Förenta staterna, 90505
        • UCLA Health Southbay Endocrine
      • Tustin, California, Förenta staterna, 92780
        • University Clin Investigators
      • Walnut Creek, California, Förenta staterna, 94598
        • Diablo Clinical Research, Inc.
    • Colorado
      • Aurora, Colorado, Förenta staterna, 80045
        • University of Colorado Hospital
    • Florida
      • Clearwater, Florida, Förenta staterna, 33756
        • Innovative Research of W Florida Inc.
      • Clearwater, Florida, Förenta staterna, 33756
        • Innovative Research of W FL
      • Miami, Florida, Förenta staterna, 33183
        • International Research Associates, LLC_Miami
    • Georgia
      • Columbus, Georgia, Förenta staterna, 31904
        • Centricity Research
    • Idaho
      • Blackfoot, Idaho, Förenta staterna, 83221
        • Elite Clinical Trials
    • Illinois
      • Peoria, Illinois, Förenta staterna, 61603
        • Methodist Medical Center of Illinois
    • Iowa
      • Iowa City, Iowa, Förenta staterna, 52242
        • University of Iowa
    • Maryland
      • Columbia, Maryland, Förenta staterna, 21045
        • Centennial Medical Group
      • Oxon Hill, Maryland, Förenta staterna, 20745
        • MD Medical Research
      • Rockville, Maryland, Förenta staterna, 20852
        • Endo And Metab Cons
    • Missouri
      • Springfield, Missouri, Förenta staterna, 65807
        • Clinvest Research
    • Montana
      • Butte, Montana, Förenta staterna, 59701
        • Mercury Str Med Grp, PLLC
    • Nebraska
      • Lincoln, Nebraska, Förenta staterna, 68510
        • Velocity Clinical Research Lincoln
    • Nevada
      • Las Vegas, Nevada, Förenta staterna, 89148
        • Palm Research Center Inc-Vegas
      • Las Vegas, Nevada, Förenta staterna, 89109
        • Excel Clinical Network
    • New York
      • Binghamton, New York, Förenta staterna, 13905
        • Velocity Clinical Research Binghamton
    • North Carolina
      • Greensboro, North Carolina, Förenta staterna, 27408
        • PharmQuest Life Sciences LLC
      • Wilmington, North Carolina, Förenta staterna, 28401
        • Accellacare Wilmington
    • Ohio
      • Canton, Ohio, Förenta staterna, 44718
        • Diab & Endo Assoc of Stark Co
      • Cincinnati, Ohio, Förenta staterna, 45242
        • Velocity Clin Res_Cincinnati
      • Cincinnati, Ohio, Förenta staterna, 45246
        • Velocity Clinical Research Springdale
      • Dayton, Ohio, Förenta staterna, 45439
        • Providence Health Partners Ctr
      • Maumee, Ohio, Förenta staterna, 43537
        • Advanced Med Res Maumee
    • Oregon
      • Grants Pass, Oregon, Förenta staterna, 97527
        • Velocity Clin Res Grants Pass
    • Pennsylvania
      • Philadelphia, Pennsylvania, Förenta staterna, 19114
        • Tristar Clin Investigations, PC
      • Pittsburgh, Pennsylvania, Förenta staterna, 15243
        • Preferred Primary Care Physicians Inc.
      • Uniontown, Pennsylvania, Förenta staterna, 15401
        • Preferred Primary Care Physicians, Inc.
    • Texas
      • Abilene, Texas, Förenta staterna, 79606
        • Velocity Clinical Research Abilene
      • Austin, Texas, Förenta staterna, 78759
        • Velocity Clin Res Austin
      • Dallas, Texas, Förenta staterna, 75390
        • UT Southwestern Med Center
      • Dallas, Texas, Förenta staterna, 75230
        • Velocity Clinical Res-Dallas
      • Dallas, Texas, Förenta staterna, 75230
        • Zenos Clinical research
      • Forney, Texas, Förenta staterna, 75126
        • Care United Research, LLC
      • Houston, Texas, Förenta staterna, 77004
        • Endocrine Associates Houston
      • Houston, Texas, Förenta staterna, 77043
        • Biopharma Informatic_Houston
      • Irving, Texas, Förenta staterna, 75039
        • Tekton Research
      • Lewisville, Texas, Förenta staterna, 75057
        • Epic Clinical Research
      • Shavano Park, Texas, Förenta staterna, 78231
        • Consano Clinical Research, LLC
    • Virginia
      • Burke, Virginia, Förenta staterna, 22015
        • Burke Internal Medicine & Research
      • Newport News, Virginia, Förenta staterna, 23606
        • TPMG Clinical Research
      • Bengaluru, Indien, 560054
        • MS Ramaiah
      • New Delhi, Indien, 110001
        • Lady Hardinge Medical College
    • Karnataka
      • Bangalore, Karnataka, Indien, 560092
        • Life Care Hospital and Research Centre
    • Kerala
      • Kochi, Kerala, Indien, 682041
        • Amrita Institute Of Medical Sciences & Research Centre
    • Madhya Pradesh
      • Indore, Madhya Pradesh, Indien, 452010
        • TOTALL Diabetes Hormone Institute
    • Maharashtra
      • Mumbai, Maharashtra, Indien, 400012
        • Seth GS Medical College & KEM Hospital
      • Pune, Maharashtra, Indien, 411021
        • Chellaram Diabetes Institute
    • Rajasthan
      • Jaipur, Rajasthan, Indien, 302006
        • Diabetes, Thyroid and Endocrine Centre
    • Tamil Nadu
      • Vellore, Tamil Nadu, Indien, 632004
        • Christian Medical College Hospital, Vellore
    • Telangana
      • Hyderabad, Telangana, Indien, 500082
        • Diabetes Research Center, Hyderabad
      • Chiba, Japan, 261-0004
        • Tokuyama clinic_Diabetic internal medicine
      • Soka-shi, Saitama, Japan, 340-0015
        • Soka Sugiura Internal Medicine Clinic
      • Tokyo, Japan, 104-0031
        • Fukuwa Clinic
      • Tokyo, Japan, 103-0027
        • Tokyo-Eki Center-building Clinic_Internal Medicine
      • Tokyo, Japan, 104-0031
        • Fukuwa Clinic_Internal Medicine
      • Québec, Kanada, G1V 4T3
        • Diex Recherche Quebec
    • British Columbia
      • Kelowna, British Columbia, Kanada, V1Y 1Z9
        • OCT Research ULC (dba Okanagan Clinical Trials)
      • Richmond, British Columbia, Kanada, V6V 2L1
        • OCT Research ULC (dba Okanagan Clinical Trials)
      • Victoria, British Columbia, Kanada, V8V 4A1
        • Cook Street Medical Clinic
    • New Brunswick
      • Moncton, New Brunswick, Kanada, E1G 1A7
        • G.A. Research Associates Ltd.
    • Nova Scotia
      • Halifax, Nova Scotia, Kanada, B3H 1V7
        • Nova Scotia Hlth Halifax
    • Ontario
      • Barrie, Ontario, Kanada, L4N 7L3
        • Centricity Research Barrie
      • Hamilton, Ontario, Kanada, L8L 5G8
        • Wharton Medical Clinic Clinical Trials (Hamilton)
      • Sarnia, Ontario, Kanada, N7T 4X3
        • London Road Diagnostic Clinic and Medical Centre
      • Toronto, Ontario, Kanada, M4G 3E8
        • Centricity Research Toronto
      • Toronto, Ontario, Kanada, M9V 4B4
        • Albion Finch Medical Centre
    • Quebec
      • Lévis, Quebec, Kanada, G6W 0M5
        • Centricity Research Quebec City
      • Mirabel, Quebec, Kanada, J7J 2K8
        • Centricity Research Mirabel
      • Montreal, Quebec, Kanada, H1Y 3H5
        • Recherche GCP Research
      • Saint-Laurent, Quebec, Kanada, H4T 1Z9
        • Centricity Research Ville St. Laurent VSL
    • Free State
      • Bloemfontein, Free State, Sydafrika, 9301
        • Josha Research
    • Gauteng
      • Johannesburg, Gauteng, Sydafrika, 2013
        • Wits Bara Clinical Trial Site
      • Midrand, Gauteng, Sydafrika, 1685
        • Dr A Jacovides and Partners Inc
    • KwaZulu-Natal
      • Durban, KwaZulu-Natal, Sydafrika, 4450
        • Dr Pillay's Rooms
      • eMkhomazi, KwaZulu-Natal, Sydafrika, 4170
        • Dr T Padayachee
      • Seoul, Sydkorea, 05505
        • Asan Medical Center
      • Seoul, Sydkorea, 01830
        • Nowon Eulji Medical Center, Eulji University
      • Seoul, Sydkorea, 03181
        • Kangbuk Samsung Hospital
      • Seoul, Sydkorea, 02841
        • Korea University Anam Hospital
    • Gyeonggi-do
      • Seongnam-si, Gyeonggi-do, Sydkorea, 13620
        • Seoul National University Bundang Hospital

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 75 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Female of non-childbearing potential, or male.
  • For United States (US) only: Female of childbearing potential using highly effective non-systemic methods of contraception with low user-dependency and willingness to continue using it through-out the study or male.
  • Age 18-75 years (both inclusive) at the time of signing the informed consent.
  • Diagnosed with type 2 diabetes mellitus greater than or equal 180 days before screening.
  • Stable daily dose(s) more than or equal 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without sodium-glucose co-transporter 2 (SGLT2) inhibitor.
  • Glycated haemoglobin (HbA1c) of 7.5-10.0% (58-86 millimoles per moles (mmol/mol)) (both inclusive) as assessed by central laboratory at screening.
  • Body mass index (BMI) greater than or equal 23.0 kilograms per meter square (kg/m^2).

Exclusion Criteria:

  • Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
  • Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Dosing scheme A (NNC0519-0130)

Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as subcutaneous (s.c.) injection in dose escalating manner.

NNC0519-0130 will be administered subcutaneously.

Placebo-jämförare: Dosing scheme A (Placebo)

Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods.

Placebo will be administered subcutaneously.

Experimentell: Dosing scheme B (NNC0519-0130)

Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as s.c. injection in dose escalating manner.

NNC0519-0130 will be administered subcutaneously.

Placebo-jämförare: Dosing scheme B (Placebo)

Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods.

Placebo will be administered subcutaneously.

Experimentell: Dosing scheme C (NNC0519-0130)

Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner.

NNC0519-0130 will be administered subcutaneously.

Placebo-jämförare: Dosing scheme C (Placebo)

Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods.

Placebo will be administered subcutaneously.

Experimentell: Dosing scheme D (NNC0519-0130)

Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner.

NNC0519-0130 will be administered subcutaneously.

Placebo-jämförare: Dosing scheme D (Placebo)

Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods.

Placebo will be administered subcutaneously.

Experimentell: Dosing scheme E (NNC0519-0130)

Participants will receive NNC0519-0130 at 7 dose levels once weekly as s.c. injection in dose escalating manner.

NNC0519-0130 will be administered subcutaneously.

Placebo-jämförare: Dosing scheme E (Placebo)

Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods.

Placebo will be administered subcutaneously.

Aktiv komparator: Dosing scheme F (tirzepatide)

Participants will receive tirzepatide at 6 dose levels once weekly as s.c. injection in dose escalating manner.

Trizepatide will be administered subcutaneously.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in Glycated haemoglobin (HbA1c)
Tidsram: From baseline (week 0) to 12 weeks on a given maintenance dose

Measured as percentage point (%-point)

From baseline (week 0) to 12 weeks on a given maintenance dose

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in Glycated haemoglobin (HbA1c)
Tidsram: From baseline (week 0) to end of treatment (week 36)

Measured as percentage point (%-point)

From baseline (week 0) to end of treatment (week 36)
Relative change in body weight
Tidsram: From baseline (week 0) to end of treatment (week 36)

Measured as percentage (%)

From baseline (week 0) to end of treatment (week 36)
Change in body weight
Tidsram: From baseline (week 0) to end of treatment (week 36)

Measured as kilograms (kg)

From baseline (week 0) to end of treatment (week 36)
Change in fasting plasma glucose (FPG)
Tidsram: From baseline (week 0) to 12 weeks on a given maintenance dose

Measured as millimoles per liter (mmol/L)

From baseline (week 0) to 12 weeks on a given maintenance dose
Continuous glucose monitoring (CGM): Change in time in range (TIR) 3.9-10.0 millimoles per liter (mmol/L) (70-180 milligrams per deciliter (mg/dL))
Tidsram: From baseline (week -2 to week 0) to week 22-24 and week 34-36, respectively

Measured as percentage point (%-point)

From baseline (week -2 to week 0) to week 22-24 and week 34-36, respectively
Change in waist circumference
Tidsram: From baseline (week 0) to end of treatment (week 36)

Measured as centimeter (cm)

From baseline (week 0) to end of treatment (week 36)
Change in systolic blood pressure (SBP)
Tidsram: From baseline (week 0) to end of treatment (week 36)

Measured as millimeters of mercury (mmHg)

From baseline (week 0) to end of treatment (week 36)
Change in high sensitivity C-Reactive Protein (hsCRP)
Tidsram: From baseline (week 0) to end of treatment (week 36)

Measured as ratio to baseline

From baseline (week 0) to end of treatment (week 36)
Change in total cholesterol
Tidsram: From baseline (week 0) to end of treatment (week 36)

Measured as ratio to baseline

From baseline (week 0) to end of treatment (week 36)
Change in high-density lipoprotein (HDL) cholesterol
Tidsram: From baseline (week 0) to end of treatment (week 36)

Measured as ratio to baseline

From baseline (week 0) to end of treatment (week 36)
Change in low-density lipoprotein (LDL) cholesterol
Tidsram: From baseline (week 0) to end of treatment (week 36)

Measured as ratio to baseline

From baseline (week 0) to end of treatment (week 36)
Change in triglycerides
Tidsram: From baseline (week 0) to end of treatment (week 36)

Measured as ratio to baseline

From baseline (week 0) to end of treatment (week 36)
Number of adverse events
Tidsram: From baseline (week 0) to end of study (week 40)

Measured as number of events

From baseline (week 0) to end of study (week 40)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studierektor: Clinical Transparency (dept. 2834), Novo Nordisk A/S

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

18 mars 2024

Primärt slutförande (Faktisk)

19 september 2025

Avslutad studie (Faktisk)

13 oktober 2025

Studieregistreringsdatum

Först inskickad

16 mars 2024

Först inskickad som uppfyllde QC-kriterierna

16 mars 2024

Första postat (Faktisk)

22 mars 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

21 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

18 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • NN9541-4945
  • U1111-1291-9196 (Annan identifierare: World Health Organization (WHO))
  • jRCT2031230704 (Registeridentifierare: JRCT)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera